On the pathogenesis and therapy of dementia of the Alzheimer type: some neuropathological, biochemical, genetic and pharmacotherapeutic considerations.
The extensive literature on dementia of Alzheimer type (DAT) testifies to the enormous progress achieved in the clinical and biochemical delineation of this disease. Newly developed laboratory and imaging techniques are also being applied to the diagnosis of DAT. Nevertheless, unequivoval diagnosis still relies primarily on morphological data from biopsy or autopsy. An overview is presented of major morphological changes occurring at different levels of organization in the central nervous system (CNS) in DAT. Currently formulated etiopathogenic hypotheses of DAT are reviewed and discussed in the context of morphological alterations. Some of the recombinant DNA methods, that are currently available for gene analysis, are described. Some approaches for studying Alzheimer specific genes using the above methods have been suggested. Finally, a critical overview of the current pharmacotherapeutic armamentarium used in DAT and senile dementia is presented. The efficacy, side effects, and the main mechanisms of action of the two categories of drug therapy -supposed etiopathogenic and symptomatic- are presented.
D000535:Aluminum / Q000633:toxicity; D000544:Alzheimer Disease / Q000188:drug therapy / Q000209:etiology* / Q000235:genetics; D001284:Atrophy; D001483:Base Sequence; D001921:Brain / Q000473:pathology; D004247:DNA / Q000032:analysis; D004314:Down Syndrome / Q000150:complications; D006801:Humans; D018377:Neurotransmitter Agents / Q000502:physiology; D009857:Oncogenes; D011110:Polymorphism, Genetic
D018377:Neurotransmitter Agents; D004247:DNA; D000535:Aluminum